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Background: Obstructive Sleep Apnoea (OSA) is associated with increased oxidative stress.
NADPH oxidases are the main source of Reactive Oxygen Species (ROS) in the vasculature.
Several polymorphisms related to NADPH oxidase expression or activity have been identified.
We compared the distribution of the allelic frequencies of A-930G and C242T polymorphisms
and their possible relationship with the levels of 8-isoprostanes as a marker of oxidative stress
in patients with OSA and in a control group without OSA.
Methods: This is a case-control study. We determined the A-930G and C242T p22phox geno-
types in 427 patients with OSA and in 139 healthy subjects recruited from the Sleep Unit of
Son Dureta University Hospital, (Palma de Mallorca, Spain). 8-Isoprostane was measured as
an oxidative stress marker.
Results: The distribution of the p22phox genotypes in OSA and in control subjects was
different. The risk of OSA was associated with the presence of the G allele in the A-930G
p22phox independently of age, gender, Body Mass Index (BMI), hypertension, dyslipemia andvestigacio´n, Hospital Universitario Son Espases, Ctra Valldemossa 79, 07120 Palma de Mallorca, Spain.
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NADPH oxidase p22phox polymorphisms 1749diabetes, but no association was found with the C242T polymorphism. The median level of 8-
isoprostane was significantly higher in OSA patients. Synergic effect in 8-Isoprostane levels was
observed when these two polymorphisms were analysed together.
Conclusion: the A-930G polymorphism of the p22phox gene may play an important role in
genetic susceptibility to OSA. Furthermore, the C242T and A-930G polymorphisms of the
p22phox gene have a synergic effect on the 8-isoprostane levels, suggesting that they may
be involved in the development of oxidative stress in these patients.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Obstructive sleep apnoea syndrome (OSA) is a common
disorder characterised by the occurrence of numerous
episodes of absence of respiratory flow (apnoea) during
sleep.1 These episodes cause repetitive cycles of hypoxia/
re-oxygenation. The treatment for OSA is the Continuous
Positive Airway Pressure (CPAP) that corrects the apnoeas
and consequently these episodes.
Experimental and clinical data have provided support for
an association between OSA and oxidative stress.2e8
Oxidative stress is caused by an imbalance between the
production of Reactive Oxygen Species (ROS) and a biolog-
ical system’s ability to readily detoxify the reactive inter-
mediates or easily repair the resulting damage.
Themajor source of ROS in the vasculature are the NADPH
oxidases or noxes, the only enzyme family whose sole func-
tion is to generate ROS.9,10 Vascular isoforms generate
superoxide anion (O2
) constitutively at a low rate for physi-
ological purposes. A variety of stimuli induce an increased
superoxide production. O2
 and its metabolite H2O2 serves as
a second messenger to activate multiple intracellular sig-
nalling pathways.9e11 The signalling pathways leading to the
expression redox-sensitive genes are themost affectedones,
resulting in the production of adhesion molecules, chemo-
tactic factors, inflammatory mediators and vasoactive sub-
stances.2,12e14 NADPH oxidases are multicomponent
enzymes consisting of cytosolic accessory proteins (Rac,
p47phox, p67phox) which after stimulation associate with
themembrane catalytic subunits (Nox, p22phox) to facilitate
superoxide generation.11 The p22phox subunit has a central
role to the normal functioning of the oxidases because it
stabilises the large subunit and serves as docking site to the
cytosolic factors. The p22phox subunit is functionally critical
for the enzymatic activity,15 and all vascular NADPH oxidases
appear to have an obligatory need for it.16
Several polymorphisms of CYBA, the gene encoding
p22phox, have been identified: I)The A-930G poly-
morphism: located in the promoter, the G allele is associ-
ated with a higher promoter activity17,18 and an increased
level of oxidative stress.19,20 II) The C242T polymorphism
(rs4673) is located in the exon 4 of the CYBA gene, leading
to a his72-to-tyr (H72Y) substitution. The T allele is asso-
ciated with significantly lower basal and stimulated
vascular superoxide production in human blood vessels
from patients with atherosclerosis, and hypertension.21
Furthermore, in healthy volunteers, neutrophil oxidative
bursts increase from the TT to the CC genotype.15
We hypothesised an existing association between OSA
and the two polymorphisms A-930G and C242T. These twopolymorphisms might play a relevant role in the oxidative
stress in OSA patients. To asses this hypothesis, we
compared the distribution of the allelic frequencies of A-
930G and C242T polymorphisms and their possible rela-
tionship with the levels of 8-isoprostanes as a marker of
oxidative stress in one group of patients with OSA and in
a control group without OSA.
Methods
Subjects and ethics
This is a caseecontrol study. Participants were recruited
between January 2007 and June 2009. A total of 427
patients with OSA were included in the study along with 139
subjects without OSA. Both cases and controls were
recruited from all individuals suspected of having OSA
referred to the Sleep Unit from primary care services of
Palma de Mallorca. Exclusion criteria (for both cases and
controls) were presence of chronic obstructive pulmonary
disease, liver cirrhosis, thyroid dysfunction, rheumatoid
arthritis, chronic renal failure and/or psychiatric disorders.
Participants were afterwards studied at the Sleep Unit of
Son Dureta University Hospital, (Palma de Mallorca, Spain).
The diagnosis of OSA was established by full poly-
somnography (E-Series; Compumedics, Abbotsford,
Australia), and included recording of oronasal flow and
thoracoabdominal movements, ECG, submental and preti-
bial electromyography, electrooculography, electroen-
cephalography and transcutaneous measurement of arterial
oxygen saturation. Apnoea was defined by the absence of
airflow for more than 10 s. Hypopnoea was defined as any
airflow reduction that lasted more than 10 s and resulted in
arousal or oxygen desaturation. We considered desatura-
tion a decrease in SaO2 greater than 4%.The apnoea/
hypopnoea index (AHI) was defined as the number of
apnoeas plus hypopnoeas per hour of sleep. OSA was diag-
nosed when the AHI was over 10 events h1. Individuals
were considered as controls if the AHI was lower than 10
events h1. Arterial hypertension was diagnosed if systolic
blood pressure (SBP) was 140 mmHg or diastolic blood
pressure (DBP)  90 mmHg. Similarly, the threshold for
diabetes was a glucose level of 126 mg dL1; for insulin
resistance, a Homeostasis Model Assessment (HOMA)22
index of 4; for dyslipemia, a total cholesterol level of
200 mg dL1 or triglycerides levels of 200 mg dL1; and for
obesity, a BMI of 30 kg m2.
The present studywas approved by the ethics committees
of the participating institutions, and all participants signed
their informed consent after being fully explained about its
1750 J. Pie´rola et al.goal and characteristics. This project has been developed
according to the STREGA statement recommendations.23
Measurements
Blood samples (10 mL) were obtained at 08:00 AM after an
overnight fast, and collected in tubes containing ethyl-
enediamine tetra-acetic acid (EDTA) and in tubes without
anticoagulant for biochemical determinations. After centri-
fugation, serum and plasma were immediately separated
into aliquots and stored at 80 C. From the EDTA tubes,
buffy coat was taken to isolate DNA of the leucocytes.
Biochemical analysis
Glucose, triglyceride, total cholesterol and HDL cholesterol
(HDLc) concentrations were determined by standard enzy-
matic methods using a Hitachi 917 biochemical analyser
(Roche Diagnostics, Manheim, Germany). The plasma
concentration of insulin and high sensitivity C- reactive
protein (CRP) were measured by commercial chemilumi-
nescent assays using an Immulite 2000 analyser (Siemens
Diagnostics, Llamberis, United Kingdom) in serum. Insulin
resistance was calculated using the HOMA index. 8-
Isoprostanes were measured with an 8-isoprostane EIA kit
(Cayman Chemicals Company, USA) in plasma samples.
DNA extraction and genotyping
DNA isolation of each blood sample was performed from
EDTA tubes using a DNA extraction Kit (Wizard Genomic;
Promega Corporation, Madison, WI, USA). Each poly-
morphism was genotyped by a specifically designed
Restriction Fragments Length Polymorphism (RFLP) method
and validated by sequencing the codifying region for both
polymorphisms. The Polymerase Chain Reaction (PCR)
primers were 50GGAAACCACCAAGTGCCTCGGATGG30 and
5TCTGCACCCTGATGCTACCAAGGAC30 for p22phox A-930G
polymorphism and 50CTCTGTTTGTCTTCAGTAAAGG30 and
50ACTCACAGGAGATGCAGGACG30 for p22phox C242T. PCRs
were carried out in a volume of 30 ml, containing 30 ng
genomic DNA, 2.0 mM, MgCl2, 200 mM deoxyribonucleoside
triphosphates, 300 nM primers, 0.025 U EuroTaq DNAFigure 1 Gentyping p22Phox polymorphisms by RFLP’s. Repres
reaction and a digestion of different genotypes for p22phox C242Tpolymerase (Euroclone, Pero, Italy) and 1x reaction buffer.
Amplified products were digested with 3 U of RsaI restric-
tion enzyme for 1 h at 37 C (New England Biolabs, Beverly,
MA, USA) for the C242T amplification product and with 3 U
of BbvI restriction enzyme for 1 h at 37 C (New England
Biolabs, Beverly, MA, USA) for the A-930G amplification
product. The resulting fragments were separated on 1.5%
agarose (Invitrogen) and visualised with ethidium bromide
staining under ultraviolet illumination (Syngene Gen
Genius; Synoptics Group, Cambridge, UK) (Fig. 1).
Statistical analysis
Results are presented as mean  standard deviation,
median, frequency or percentage as required. Continuous
variables were analysed using the Student’s t-test and
ANOVA, whereas categorical variables were analysed using
the c2 test. Non-parametric tests (ManneWhitney U test,
KruskaleWallis) were used for variables that were not nor-
mally distributed.
The HardyeWeinberg equilibrium for allelic distribution
was tested using the formula 1Z p2þ2pqþ q2,where p and q
are the allelic frequencies of C and T in C242T polymorphism
and A and G in the A-930G, respectively. In both poly-
morphisms the allelic frequencies were in HardyeWeinberg
equilibrium. This is a logistic regression and it has already
been explained below. Note that, at least in our population,
the C242T polymorphism is not in linkage disequilibriumwith
the A-930G polymorphism, as has been published in the
Caucasian population.24
The adjusted association between genotypes and OSA
was examined using binomial logistic regression. A p-value
< 0.05 was considered significant.
Results
Subject characteristics, allelic, genotype
frequencies
Demographic and clinical characteristics are summarised in
Table 1. The allelic and genotypic distribution of the
A-930G and C242T polymorphisms is represented in Tables 2
and 3 respectively. In the A-930G polymorphism theentative agarose gel (1.5%) showing the genotyping by PCR
and A-930G polymorphisms.
Table 1 Demographic and clinical characteristics.
Sample characterisation OSA Mean  SD CONTROL Mean  SD
N 427 139
Age (years)** 51  12 45  12
Men n (%)** 352 (82%) 89 (74%)
Body Mass Index (kg m2)** 31.4  6 27.9  5
Obesity n (%)** 237 (56%) 42 (31%)
Epworth Scale** 10  5 8  4
AHI (events h1)** 48  24 3  2
SBP (mmHg)** 131  17 121  16
DBP (mmHg)** 80  12 76  11
Hypertension n (%)** 204 (49%) 33 (24%)
Glucose (mg/dl)** 106  23 93  15
Diabetes n (%)* 77 (18%) 13 (9%)
Dyslipemia n (%)** 272 (64%) 66 (55%)
Cholesterol(mg/dL) 207  40 206  40
Triglycerides (mg/dL)** 159  101 120  50
CRP (mg/l)** 3.01  2.36 2.14  2.15
Insulin (mlU/ml) 14.2  9.8 16  21
HOMA index 3.9  3 3.8  5.5
*p < 0.05; **p < 0.01.
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between our groups (0.64 for OSA and 0.55 for control
group, p Z 0.091) and in the C242T polymorphism, the
prevalence of the C allele was also not significantly
different between the groups (0.66 for OSA and 0.60 for the
control group, pZ 0.337). However, the prevalence of the
genotypes was different between cases and controls in A-
930G polymorphism (38.9% for GG, 49.9% for AG and 11.2%
for AA in OSA patients and 29.6% for GG, 47.4% for AG and
23% for controls, p Z 0.002) and also in C242T poly-
morphism (10.3% for TT, 48% for CT and 41.7% for CC in OSA
patients and 18.7% for TT, 42.4% for CT and 38.8% for
controls, p Z 0.033).Genetic association analysis
We genotyped the A-930G and C242T p22Phox poly-
morphisms in DNA isolated from the leukocytes of the
participants. When we analysed the relationship of the
p22pPhox polymorphisms with OSA, we detected that the G
allele of the A-930G polymorphism is associated with OSA
following a dominant model independently of age, obesity,
gender, hypertension and diabetes (Table 4, p Z 0.012 for
AGvs.AA and p Z 0.006 for GGvs.AA). The C242T was
associated with OSA in the crude analysis, but this associ-
ation disappears when we adjusted for age, obesity, genderTable 2 Allelic and genotype frequencies for p22phox A-930G.
OSA patients n (%)
Genotype GG 163 (38.9)
Genotype GA 209 (49.9)
Genotype AA 47 (11.2)
G Allelic frequency 0.64
A Allelic frequency 0.36and hypertension (Table 4). Interaction between both
polymorphisms was not significant.
Differences in 8-isoprostane levels between OSA
and control group
The median level of 8-isoprostane was significantly higher
(p Z 0.001) in OSA patients (12.10 ng dL1 (IQR:
6.23e23.98)) than in the control group (5.07 ng dL1 (IQR:
1.41e11.56)).
Patients with the GG genotype for the A-930G poly-
morphism had significantly higher 8-Isoprostane levels
compared to those with the AG or AA genotype (pZ 0.001).
Patients with the CC genotype for the C242T polymorphism
had significantly higher 8-Isoprostane levels than those
subjects with the CT or TT genotype (p Z 0.009).
Furthermore, synergic effect was observed when these two
polymorphisms were analysed together (Fig. 2).
Discussion
This study provides evidence of a relationship between the
p22phox A-930G polymorphism and OSA independently of
age, obesity, gender, hypertension, dyslipemia and
diabetes.
OSA is thought to be a complex disorder that involves
multiple genes,environmental influences andControls n (%) p Value
40 (29.6) 0.002
64 (47.4)
31 (23.0)
0.55 0.091
0.45
Table 3 Allelic and genotype frequencies for p22phox C242T.
OSA Patients n (%) Controls n (%) p-value
Genotype TT 43 (10.3) 26 (18.7) 0.033
Genotype CT 200 (48.0) 59 (42.4)
Genotype CC 174 (41.7) 54 (38.8)
T Allelic frequency 0.34 0.40 0.337
C Allelic frequency 0.66 0.60
1752 J. Pie´rola et al.developmental factors.25The role of specific genes that
influence the development of OSA is not clear. Previous
studies have reported that several single nucleotide poly-
morphisms (SNPs) such as serotonin transporter (5-HTT)26 or
ApoE27,28 might be involved in the pathogenesis of OSA. Our
results show different allelic frequencies of the A-930G
polymorphism between OSA patients and controls. The G
allele of this polymorphism was associated with sleep
apnoea independently of age, obesity, gender, hyperten-
sion, and diabetes and C242T polymorphism. Furthermore,
carriers of the AG and GG genotype had also a higher risk of
developing OSA (odds ratio 2.209 and 2.536 respectively,
Table 4). These results suggest that the A-930G poly-
morphism might be a genetic maker for OSA. In our results
the role of the p22phox C242T polymorphism is not signifi-
cant because it depends on the factors cited before.
We analysed the relationship of these polymorphisms
with the severity of OSA and EDS without significance for
AHI or Epworth index in OSA patients (data not shown).
A different rate of p22phox expression due to different
promoter activity17,18 has been described for the A-930G
polymorphism. G allele is associated with higher p22phox
expression and an increased level of oxidative stress.19,20
Oxidative stress is not only a characteristic of OSA but
also an important component in the associated conditions
and comorbidities that aggregate with it, such as sympa-
thetic activation, obesity, hypertension, hyperlipidemia
and diabetes mellitus.2,3,8 Since in our results A-930G
polymorphism is associated with sleep apnoea indepen-
dently of these comorbidities, we conclude that anTable 4 Association between the P22phox polymorphisms
and OSA adjusted for clinical characteristics. Logistic
regression.
Characteristics Odds ratio (CI 95%)
Age** 1.03 (1.01e1.05)
Obesity** 2.89 (1.80e4.63)
Sex (Male vs. Female)** 3.45 (2.07e5.74)
Hypertension* 1.70 (1.01e2.86)
Diabetes 1.86 (0.85e4.05)
242T poymorphism
Genotype CT (vs. CC) 1.25 (0.77e2.03)
Genotype TT (vs. CC) 0.67 (0.34e1.31)
A-930G polymorphism
Genotype AG (vs. AA)* 2.21 (1.19e4.10)
Genotype GG (vs. AA)** 2.54 (1.31e4.90)
*p < 0.05; **p < 0.01.increased tendency to oxidative stress might be a risk
factor for OSA.
For the C242T polymorphism a different rate of O2-
production has been demonstrated depending on the
genotype. The T allele is associated with a reduced NADPH
oxidase, in a basal or stimulated activity.15,29 The presence
of this allele has been suggested to be protective to several
pathologies such as atherosclerosis29,30 and hypertension.21
A recent meta-analysis showed that the T allele seems to
have a protective effect against Coronary Artery Disease
(CAD) in Asian population.31 However, high heterogeneity
has been demonstrated within ethnic groups showing
controversial results.
In our study different allelic frequencies of p22phox
C242T between OSA and the control group are shown (Table
3). However, the significance in the relationship between
OSA and C242T polymorphism depends on the confounding
factors included in the analysis (age, obesity, gender,
hypertension, diabetes and the A-930G polymorphism. The
relationship of C242T polymorphism with OSA has been
studied in the Chinese Han population.32 In contrast to our
results, this study suggested that the T allele contributes to
the susceptibility to OSA. The different results of the Han
study could be due to the high heterogeneity within ethnic
groups or to the fact that confounding factors were not
included in the analysis. Similar differences between Asian
and Caucasian population in the allelic frequencies were
found in the analysis of this polymorphism in coronary
artery disease.31
In order to analyse the role of oxidative stress as the link
of the relationship OSA-p22phox polymorphisms, we
measured the 8-isoprostane levels. 8-Isoprostane levels
were significantly higher in the OSA group than in the
control group. These data confirmed previous reporting of
increased oxidative stress in OSA patients.
In our results carriers of the G allele presented higher 8-
isoprostane levels than those with the A allele. In the case
of the C242T polymorphism the presence of the C allele was
related to higher 8-isoprostane levels. Furthermore, an
interesting finding of our study was the already described
synergic effect of the A-930G and the C242T polymorphisms
in hypertensive patients21 but on the 8-Isoprostane levels
(Fig. 2) in OSA patients. This means that the concurrence of
the 930 GG and 242CC genotypes associates with greater
8-Isoprostane levels in OSA patients and also the concur-
rence of the 930AA and 242 TT genotypes associates with
lower 8-Isoprostane levels in OSA patients.
In interpreting the results of our study several limita-
tions should be considered. First, although we have
measured 8-Isoprostane as oxidative stress indicator we
have not directly quantified the NADPH oxidase activity.
Figure 2 Synergic effect of the polymorphisms on the 8-Isoprostane level. Box plot of the distribution of 8-Isoprostane levels
among combined genotypes of C242T and A-930G p22phox gene in patients with OSA. The median is shown as a line across the-
box, the bottom and the top of the box indicate from 25th to 75th percentiles. Bars indicate the 1.5-fold of the whole box length.
* p < 0.005 compared with other combinations. þ p < 0.005 compared with other combinations.
NADPH oxidase p22phox polymorphisms 1753Second, we have not analysed the NADPH oxidase expres-
sion in relationship with both polymorphisms, but it has
been already described in previous studies.15,18,24,29 More-
over, no replication study in another group has been done.
Conclusions
In conclusion, the present results support our hypothesis
that the A-930G polymorphism of the p22phox gene may
play an important role in genetic susceptibility to OSA.
Furthermore, the C242T and A-930G polymorphisms of the
p22phox gene have a synergic effect on the 8-isoprostane
levels, suggesting that they may be involved in the devel-
opment of oxidative stress in these patients. Further
studies are required to describe the exact role of p22phox
gene and NADPH oxidase in the pathogenesis of obstructive
sleep apnoea.
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